

## Agenda

*Q&A After Each Session Moderated by Dr Huggins-Puhalla and Dr. Mehta*

7:15 am	Registration and TEAMS login	
8:00 am	Welcome	Dhaval Mehta, MD Shannon Huggins-Puhalla, MD
8:10 am	Basic Science Update: <b>Study 21-048</b> : Platelet-based biomarkers	Richard Steinman, MD, PhD
8:30 am	ER+ Early Stage: <b>GS1-01</b> : Race and Outcome in RxPONDER, <b>GS1-02</b> : Racial Disparity in Tumor Microenvironment and Outcomes in Residual Disease Treated with NAC, and <b>GS4-09</b> : POSITIVE Trial	Kit Lu, MD
8:45 am	<b>GS1-06</b> : BCI in SOFT trial and <b>GS5-10</b> : Mammprint and Extended Endocrine Therapy	Mohammad (Pervaiz) Rahman, MD
9:10 am	ER+ Advanced Stage: <b>SERD/PROTAC</b> <b>GS3-01</b> : EMERALD, <b>GS3-02</b> : Camizestrant, and <b>GS3-03</b> : ARV-471 (High priority NRG trials)	Charles Geyer, MD
9:25 am	<b>Non-SERD</b> : <b>GS3-04</b> : Capivasertib, <b>GS3-06</b> : PACE Trial, <b>GS1-10</b> : RIGHT Choice, and <b>GS3-09</b> : CTC-Driven Choice of First Line Therapy for ER+HER2- MBC-STIC CTC Trial	Vikram Gorantla, MD
9:50 am	HER2 Low: <b>GS203</b> : TALENT (Summary of Abstracts in HER2 Low Session and Overview of High Priority Trials)	Adam Brufsky, MD, PhD, FACP
10:15 am	Break	
10:30 am	HER2+: <b>GS2-01</b> : DB02, <b>GS2-02</b> : DB03, and <b>GS1-09</b> : MONARChE update	Priya Rastogi, MD
10:50 am	TNBC and Immunotherapy: <b>GS5-11</b> : TROPICS 02 Survival Data, <b>GS5-02</b> : GeparOLA, and <b>GS5-03</b> : I-SPY cemiplimab	Julia Foldi, MD, PhD
11:15 am	Brinker Lecture	Norman Wolmark, MD, FACS, FRCS
12:00 pm	Lunch	
12:45 pm	Genetics and Prevention: <b>GS4-04</b> : Risk of Contralateral Breast Cancer with Gene Mutations and <b>GS4-08</b> : Low Dose Tamoxifen Update	Phoung Mai, MD, MS
1:10 pm	Breast Surgery: <b>GS4-01</b> : BCS and Multiple IPSI Breast Cancers and <b>GS4-02</b> : Omission of ALND with Conversion to Node (-)	Emilia Diego, MD
1:30 pm	Radiation: <b>GS4-03</b> : POLAR Trial, <b>GS4-05</b> : Phase II Randomized Trial of Conventional vs. Hypofractionated Post-Mastectomy Proton Radiotherapy, <b>GS4-06</b> : Radiomic Phenotypes of Breast Texture and Association with Breast Cancer Risk and Masking, and <b>GS5-12</b> : Hypofractionated Radiotherapy in Patients with Breast Cancer: Acute Toxicity Data of a Phase III Randomized Study	Parul Barry, MD
1:55 pm	Conclusion	Dhaval Mehta, MD Shannon Huggins-Puhalla, MD
2:00 pm	Adjournment	